Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of cisplatin plus metronomic cyclophosphamide in metastatic triple-negative breast cancer
2012-005213-39Phase 2Active
- Sponsor
- Centre Jean Perrin
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and cyclophosphamide in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Centre Jean Perrin. Primary endpoint: Treatment response rate. Started Apr 2013; status: active.
02
Drugs
cisplatincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2012-005213-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005213-39.